Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer
Pharmaceutical Technology
SEPTEMBER 5, 2023
Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.
Let's personalize your content